Mar 15, 2022 / 05:20PM GMT
Suraj Kalia - Oppenheimer & Co. Inc., Research Division - MD & Senior Analyst
Good afternoon, everyone. Suraj Kalia, senior medical device analyst at Oppenheimer. Pleased to have so many of you join us this afternoon for a fireside chat with Rob Douglas, Chief Operating Officer of ResMed.
Rob, it's a pleasure to have you here. I'll let you take the floor for a couple of minutes for some introductory comments, and we'll jump into the meat of the matter.
Robert A. Douglas - ResMed Inc. - President & COO
Great. Thanks, Suraj. Great to be here, and thanks, everyone, for joining. For those of you who don't know, ResMed, we're a world-leading digital health company. Our sort of -- the digitization of our entire therapy platform has really made a huge difference to the company. And at this stage, we have well over 16 million cloud-connected devices treating people every day.
We also have a software business. We have over 115 [million] (added by company after the call) patient accounts in that software business, providing management of
Resmed Inc at Oppenheimer Healthcare Conference (Virtual) Transcript
Jan 23, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers